Results announcement for the first quarter 2013

Wednesday 24 April 2013, London UK

GSK delivers Q1 2013 core EPS of 26.9p and dividend of 18p

  • Core EPS of 26.9p and dividend of 18p
  • Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons
  • Continued R&D pipeline progress
  • Continued delivery of financial efficiencies, strong cash generation and returns to shareholders
  • Further measures to drive strategic focus and improve growth profile
  • 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)

View full Q1 2013 announcement PDF

More details with CFO interview available in the quarterly results section of this website.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

GlaxoSmithKline Enquiries:

 

 

 

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502

(London)

 

David Daley

+44 (0) 20 8047 5502

(London)

 

Catherine Hartley

+44 (0) 20 8047 5502

(London)

 

 

 

 

US Media enquiries:

Stephen Rea

+1 215 751 4394

(Philadelphia)

 

Kevin Colgan

+1 919 483 2933

(North Carolina)

 

Melinda Stubbee

+1 919 483 2510

(North Carolina)

 

Mary Anne Rhyne

+1 919 483 0492

(North Carolina)

 

Sarah Alspach

+1 202 715 1048

(Washington, DC)

 

Jennifer Armstrong

+1 215 751 5664

(Philadelphia)

 

 

 

 

Analyst/Investor enquiries:

Ziba Shamsi

+ 44 (0) 20 8047 3289

(London)

 

Lucy Budd

+44 (0) 20 8047 2248

(London)

 

Tom Curry

+ 1 215 751 5419

(Philadelphia)

 

Gary Davies

+ 44 (0) 20 8047 5503

(London)

 

James Dodwell

+ 44 (0) 20 8047 2406

(London)

 

Jeff McLaughlin

+ 1 215 751 7002

(Philadelphia)

GlaxoSmithKline cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2012.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.